-

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday, November 30, 2021, beginning at 1:25 p.m. Eastern Time.

A webcast of the event will be accessible on the Investor Calendar page under the News & Events heading of Cortexyme’s investor website at ir.cortexyme.com. The webcast will be archived at that location for 90 days.

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain of Alzheimer’s patients and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Contacts

Stacy Roughan
Vice President, Corporate Communications & Investor Relations
Cortexyme, Inc.
ir@cortexyme.com

Industry:

Cortexyme, Inc.

NASDAQ:CRTX
Release Versions
English
$Cashtags
$CRTX

Contacts

Stacy Roughan
Vice President, Corporate Communications & Investor Relations
Cortexyme, Inc.
ir@cortexyme.com

More News From Cortexyme, Inc.

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patie...

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers i...

Quince Therapeutics to Participate at Investor Events in December 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025: Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025,...
Back to Newsroom